Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

INTRODUCTION: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) improve hepatic dysfunction, although studies focusing on their underlying mechanisms are lacking, especially ones on dapagliflozin and empagliflozin. Here, we investigated the relationship between amelioration of hepatic dysfunction...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Paul Chi Ho, Gu, Yunjuan, Yeung, Man Yi, Fong, Carol Ho Yi, Woo, Yu Cho, Chow, Wing Sun, Tan, Kathryn, Lam, Karen Siu Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801241/
https://www.ncbi.nlm.nih.gov/pubmed/29322486
http://dx.doi.org/10.1007/s13300-017-0355-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801241/
https://www.ncbi.nlm.nih.gov/pubmed/29322486
http://dx.doi.org/10.1007/s13300-017-0355-3

Ejemplares similares